Patterns of antiseizure medication use in pregnant women with epilepsy: a 24-year observation in Poland
- PMID: 39945577
- DOI: 10.5603/pjnns.102936
Patterns of antiseizure medication use in pregnant women with epilepsy: a 24-year observation in Poland
Abstract
Aim of study: The aim of this study was to examine trends in the usage of antiseizure medications (ASM) in pregnant women with epilepsy (WWE) in Poland across 24 years.
Clinical rationale for study: Most WWE continue ASM treatment during pregnancy. Over recent decades, third-generation ASMs with different safety profiles have become available. Understanding the long-term trends could provide valuable information for improving clinical practice guidelines.
Material and methods: The study is based on prospectively collected data from an institutional database of a tertiary epilepsy centre between 2000 and 2024. Data on ASM use during pregnancy was recorded at conception and each trimester. Trends in ASM use in monotherapy and polytherapy were analysed. The study included 1,454 completed pregnancies with a known outcome and a mean maternal age of 28.99 years.
Results: WWE were exposed to 19 different ASMs in monotherapy or polytherapy. Lamotrigine (LTG), valproate (VPA), carbamazepine (CBZ) and levetiracetam (LEV) accounted for 82% of all ASMs. Between 2000 and 2024, there was a statistically significant decrease in the usage of CBZ (Exp(B) = 0.92; p < 0.001; 8% annually) and of VPA (Exp(B) = 0.95; p = 0.005, 5% annually) and an increase in the use of LTG (Exp(B) = 1.03; p = 0.086; 3% annually) and of LEV (Exp(B) = 1.19; p < 0.001; 19% annually). More than two-thirds of the women were on monotherapy, both at conception and throughout pregnancy. WWE not exposed to ASMs accounted for 13.9% at conception and 10.5% in all trimesters. There was a significant increase in the number of women receiving polytherapy across all trimesters over time (Exp(B) = 1.02; p = 0.052; 2% annually) and a decrease in untreated women across all trimesters over time (Exp(B) = 0.97; p = 0.033; 3% annually). The mode of treatment at conception did not change statistically over time.
Conclusions/clinical implications: The use of specific ASMs h as c hanged s ignificantly in th e 21 st ce ntury, wi th a no table decrease in the usage of CBZ and VPA in favour of LEV and LTG. There is an increasing trend towards polytherapy across all trimesters, but not at the conception point.
Keywords: anti-seizure medication; drug utilisation trend; pregnancy; women with epilepsy.
Similar articles
-
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. doi: 10.3310/hta9150. Health Technol Assess. 2005. PMID: 15842952
-
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.Cochrane Database Syst Rev. 2016 Nov 7;11(11):CD010224. doi: 10.1002/14651858.CD010224.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2023 Aug 29;8:CD010224. doi: 10.1002/14651858.CD010224.pub3. PMID: 27819746 Free PMC article. Updated.
-
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.Cochrane Database Syst Rev. 2017 Jun 29;6(6):CD011412. doi: 10.1002/14651858.CD011412.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2017 Dec 15;12:CD011412. doi: 10.1002/14651858.CD011412.pub3. PMID: 28661008 Free PMC article. Updated.
-
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.Cochrane Database Syst Rev. 2017 Dec 15;12(12):CD011412. doi: 10.1002/14651858.CD011412.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2022 Apr 1;4:CD011412. doi: 10.1002/14651858.CD011412.pub4. PMID: 29243813 Free PMC article. Updated.
-
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.Cochrane Database Syst Rev. 2023 Aug 29;8(8):CD010224. doi: 10.1002/14651858.CD010224.pub3. Cochrane Database Syst Rev. 2023. PMID: 37647086 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials